These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26908738)

  • 1. Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine.
    Chesson HW; Laprise JF; Brisson M; Markowitz LE
    J Infect Dis; 2016 Jun; 213(11):1694-700. PubMed ID: 26908738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
    Chesson HW; Markowitz LE; Hariri S; Ekwueme DU; Saraiya M
    Hum Vaccin Immunother; 2016 Jun; 12(6):1363-72. PubMed ID: 26890978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection.
    Choi W; Shim E
    Prev Med; 2024 Jan; 178():107743. PubMed ID: 37866695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Vaccine; 2018 Jul; 36(29):4362-4368. PubMed ID: 29887325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
    Wondimu A; Postma MJ; van Hulst M
    Vaccine; 2022 Mar; 40(14):2161-2167. PubMed ID: 35248423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
    De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
    Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom.
    Owusu-Edusei K; Palmer C; Ovcinnikova O; Favato G; Daniels V
    J Health Econ Outcomes Res; 2022; 9(1):140-150. PubMed ID: 35795155
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
    Petrosky E; Bocchini JA; Hariri S; Chesson H; Curtis CR; Saraiya M; Unger ER; Markowitz LE;
    MMWR Morb Mortal Wkly Rep; 2015 Mar; 64(11):300-4. PubMed ID: 25811679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model.
    Chesson HW; Meites E; Ekwueme DU; Saraiya M; Markowitz LE
    Vaccine; 2020 Nov; 38(50):8032-8039. PubMed ID: 33121846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
    Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
    Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z; Zhang J; Xia N; Zhao Q
    Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.
    Cheung TH; Cheng SSY; Hsu DC; Wong QW; Pavelyev A; Walia A; Saxena K; Prabhu VS
    Cost Eff Resour Alloc; 2021 Nov; 19(1):75. PubMed ID: 34801050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
    Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study.
    Laprise JF; Drolet M; Boily MC; Jit M; Sauvageau C; Franco EL; Lemieux-Mellouki P; Malagón T; Brisson M
    Vaccine; 2014 Oct; 32(44):5845-53. PubMed ID: 25131743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
    Jit M; Brisson M; Laprise JF; Choi YH
    BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.